BioMed Research International Peptic Ulcer Diseases: Genetics, Mechanism, and Therapies Guest Editors: Seng-Kee Chuah, Deng-Chyang Wu, Hidekazu Suzuki, NeuralKhean-Lee Goh,Computation John Kao, and Jian-Lin Ren for Rehabilitation Peptic Ulcer Diseases: Genetics, Mechanism, and Therapies BioMed Research International Peptic Ulcer Diseases: Genetics, Mechanism, and Therapies Guest Editors: Seng-Kee Chuah, Deng-Chyang Wu, Hidekazu Suzuki, Khean-Lee Goh, John Kao, and Jian-Lin Ren Copyright © 2014 Hindawi Publishing Corporation. All rights reserved. This is a special issue published in “BioMed Research International.” All articles are open access articles distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Contents Peptic Ulcer Diseases: Genetics, Mechanism, and Therapies, Seng-Kee Chuah, Deng-Chyang Wu, Hidekazu Suzuki, Khean-Lee Goh, John Kao, and Jian-Lin Ren Volume 2014, Article ID 898349, 4 pages Impact of Blood Type, Functional Polymorphism (T-1676C) of the COX-1 Gene Promoter and Clinical Factors on the Development of Peptic Ulcer during Cardiovascular Prophylaxis with Low-Dose Aspirin, Pin-Yao Wang, Hsiu-Ping Chen, Angela Chen, Feng-Woei Tsay, Kwok-Hung Lai, Sung-Shuo Kao, Wen-Chi Chen, Chao-Hung Kuo, Nan-Jing Peng, Hui-Hwa Tseng, and Ping-I Hsu Volume 2014, Article ID 616018, 6 pages Comparison of Hemostatic Efficacy of Argon Plasma Coagulation with and without Distilled Water Injection in Treating High-Risk Bleeding Ulcers,Yuan-RungLi,Ping-IHsu,Huay-MinWang, Hoi-Hung Chan, Kai-Ming Wang, Wei-Lun Tsai, Hsien-Chung Yu, and Feng-Woei Tsay Volume 2014, Article ID 413095, 6 pages Consensus on Control of Risky Nonvariceal Upper Gastrointestinal Bleeding in Taiwan with National Health Insurance, Bor-Shyang Sheu, Chun-Ying Wu, Ming-Shiang Wu, Cheng-Tang Chiu, Chun-Che Lin, Ping-I Hsu, Hsiu-Chi Cheng, Teng-Yu Lee, Hsiu-Po Wang, and Jaw-Town Lin Volume 2014, Article ID 563707, 8 pages The Utilization of a New Immunochromatographic Test in Detection of Helicobacter pylori Antibody from Maternal and Umbilical Cord Serum, Fu-Chen Kuo, Chien-Yi Wu, Chao-Hung Kuo, Chia-Fang Wu, Chien-Yu Lu, Yen-Hsu Chen, Chiao-Yun Chen, Yi-Ching Lo, Ming-Tsang Wu, and Huang-Ming Hu Volume2014,ArticleID568410,6pages Predicting the Progress of Caustic Injury to Complicated Gastric Outlet Obstruction and Esophageal Stricture, Using Modified Endoscopic Mucosal Injury Grading Scale, Lung-Sheng Lu, Wei-Chen Tai, Ming-Luen Hu, Keng-Liang Wu, and Yi-Chun Chiu Volume2014,ArticleID919870,6pages Decreased Gastric Motility in Type II Diabetic Patients, Yi-Chun Chiu, Ming-Chun Kuo, Christopher K. Rayner, Jung-Fu Chen, Keng-Liang Wu, Yeh-Pin Chou, Wei-Chen Tai, and Ming-Luen Hu Volume 2014, Article ID 894087, 6 pages Outcome of Holiday and Nonholiday Admission Patients with Acute Peptic Ulcer Bleeding: AReal-WorldReportfromSouthernTaiwan, Tsung-Chin Wu, Seng-Kee Chuah, Kuo-Chin Chang, Cheng-Kun Wu, Chung-Huang Kuo, Keng-Liang Wu, Yi-Chun Chiu, Tsung-Hui Hu, and Wei-Chen Tai Volume 2014, Article ID 906531, 6 pages Diagnosis, Treatment, and Outcome in Patients with Bleeding Peptic Ulcers and Helicobacter pylori Infections, Ting-Chun Huang and Chia-Long Lee Volume2014,ArticleID658108,10pages The Effect of Helicobacter pylori Eradication on the Levels of Essential Trace Elements,Meng-ChiehWu, Chun-Yi Huang, Fu-Chen Kuo, Wen-Hung Hsu, Sophie S. W. Wang, Hsiang-Yao Shih, Chung-Jung Liu, Yen-Hsu Chen, Deng-Chyang Wu, Yeou-Lih Huang, and Chien-Yu Lu Volume 2014, Article ID 513725, 5 pages Gastrointestinal Hemorrhage in Warfarin Anticoagulated Patients: Incidence, Risk Factor, Management, and Outcome, Wen-Chi Chen, Yan-Hua Chen, Ping-I Hsu, Feng-Woei Tsay, Hoi-Hung Chan, Jin-Shiung Cheng, and Kwok-Hung Lai Volume 2014, Article ID 463767, 7 pages Does Long-Term Use of Silver Nanoparticles Have Persistent Inhibitory Effect on H. pylori Based on Mongolian Gerbil’s Model?, Chao-Hung Kuo, Chien-Yu Lu, Yuan-Chieh Yang, Chieh Chin, Bi-Chuang Weng, Chung-Jung Liu, Yen-Hsu Chen, Lin-Li Chang, Fu-Chen Kuo, Deng-Chyang Wu, and Hong-Lin Su Volume 2014, Article ID 461034, 7 pages Hindawi Publishing Corporation BioMed Research International Volume 2014, Article ID 898349, 4 pages http://dx.doi.org/10.1155/2014/898349 Editorial Peptic Ulcer Diseases: Genetics, Mechanism, and Therapies Seng-Kee Chuah,1 Deng-Chyang Wu,2 Hidekazu Suzuki,3 Khean-Lee Goh,4 John Kao,5 and Jian-Lin Ren6 1 Division of Hepato-Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, 123 Ta-Pei Road, Niao-Sung District, Kaohsiung City 833, Taiwan 2Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Medical University Hospital and Kaohsiung Medical University, Kaohsiung City 807, Taiwan 3DivisionofGastroenterology,NationalHospitalOrganizationTokyoMedicalCenter,2-5-1Higashigaoka, Meguro-ku, Tokyo 152-8902, Japan 4Department of Medicine, University of Malaysia, 50603 Kuala Lumpur, Malaysia 5Department of Internal Medicine, Division of Gastroenterology, University of Michigan, 1150 W Medical Center Drive, 6520A MSRB 1, SPC 5682, Ann Arbor, MI 48109-5682, USA 6Division of Gastroenterology, Zhongshan Hospital, Xiamen University, 201 Hubin South Road, Xiamen, Fujian 361004, China Correspondence should be addressed to Seng-Kee Chuah; [email protected] and Deng-Chyang Wu; [email protected] Received 22 September 2014; Accepted 22 September 2014; Published 28 December 2014 Copyright © 2014 Seng-Kee Chuah et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Peptic ulcer disease is a very common disease which is mainly ulcer disease, (4) peptic ulcer disease mechanism using relevant to Helicobacter pylori (H. pylori) and nonsteroid anti- model systems such as H. pylori, (5) recent advances in peptic inflammatory drugs (NSAIDs)1 [ , 2]. Recent advances in biol- ulcer disease bleeding, (6) recent advances in peptic ulcer ogy and medicine have introduced new technologies to study disease perforation and stenosis, and (7) recent advances in the genetics of and the mechanisms underlying its pathology. the relevant motility issue. Eventually, we published 11 papers Knowledge and understanding of these conditions have led overall. to the development of animal models, successful therapies, Upper gastrointestinal bleeding (UGIB) guidelines and novel tools to characterize these clinical conditions and improve patient care and outcomes [3–5]. This issue provide better care to patients. In this special issue, we invite highlights the paper entitled “Consensus on control of risky investigators to contribute original research articles as well nonvariceal upper gastrointestinal bleeding in taiwan with as review articles that will stimulate the continuing efforts to national health insurance” which highlighted the consensus understand the underlying molecular issue, the development report of Taiwan UGIB consensus meeting. It comprised of strategies to treat these conditions, and the evaluation of recommendations from a nationwide scale to improve the outcomes. Weare particularly interested in articles describing control of UGIB, especially for the high-risk comorbidity the new modalities for clinical characterization of this disease group. The consensus included 17 statements, including and measuring outcomes from treatment trials, advances in 3 on preendoscopy, 5 on endoscopy, 6 on postendoscopy molecular genetics and molecular diagnostics, and current assessment, and 3 on Taiwan NHIRD regarding UGIB. The concepts in the treatment issues such as (1) recent genetic consensus highlighted that patients with comorbidities, developments in peptic ulcer disease research such as genetic including liver cirrhosis, end-stage renal disease, probable polymorphism and peptic ulcer disease, (2) recent advances chronic obstructive pulmonary disease, and diabetes, are at in genetics and treatment of H. pylori, (3) latest technologies high risk of peptic ulcer bleeding and rebleeding. Special for clinical evaluation and measuring outcomes of peptic considerations are recommended for such risky patients, 2 BioMed Research International including raising hematocrit to 30% in uremia or acute injection in treating high-risk bleeding ulcers”observedthat myocardial infarction, aggressive acid secretory control endoscopic therapy with argon plasma coagulation (APC) in high Rockall scores, monitoring delayed rebleeding in plus distilled water injection was no more effective than APC uremia or cirrhosis, considering cycloxygenase-2 inhibitors alone in treating high-risk bleeding ulcers, whereas combined plus proton-pump inhibitors (PPI) for pain control, and therapy was potentially superior for patients with poor overall early resumption of antiplatelets plus PPI in coronary outcomes. artery disease or stroke. The consensus comprises practical UGIB is the most frequently encountered complication recommendations to improve patient care of UGIB, especially of peptic ulcer disease. H. pylori infection and nonsteroidal for those with comorbidities. The most essential point of anti-inflammatory drug (NSAID) administration are two the Taiwan consensus is that it focuses more on comorbid independent risk factors for UGIB [17–19]. The paper entitled patients. This is very